Lilly Aims For Earlier Treatment With Novel Diabetes Drugs
GLP-1/GIP Agonist Tirzepatide Leads Next-Gen Pipeline
Lilly outlined its tirzepatide-led pipeline of incretin agonists and highlighted its once-weekly basal insulin during a post-ADA event. The company hopes to grow the GLP-1 market overall rather than shift patients from Trulicity.
